Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus bendamustine and rituximab in newly diagnosed mantle cell lymphoma
jRCT2051230017Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing BR plus placebo with BR plus ibrutinib (2 arms). Primary endpoint: Progression-free survival. Started Oct 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on jRCT2051230017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230017.